| 主权项 |
1. A method of determining the presence, identity, and/or severity of a disease or condition in an individual, where the disease or condition is associated with abnormal glycan biosynthesis, degradation, or accumulation, the method comprising:
(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound(s), wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme(s), wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition, and (b) detecting the presence of and/or measuring the amount of the biomarker produced using an analytical instrument and displaying or recording the presence of or the measure of the biomarker produced; (c) correlating the presence of and/or the measure of the amount of the biomarker with the presence, identity, and/or severity of the disease or condition for determining the presence, identity, and/or severity of the disease or condition; wherein the disease or condition is a lysosomal storage disease, cancer, an inflammatory disease, a liver disease, a bone disease, an infectious disease, a central nervous system disease, or a cardiovascular disease; and wherein when the lysosomal storage disease is an MPS disorder or when the disease or condition is osteoarthritis, then the digesting glycan enzyme is not a lyase. |
